Johnson & Johnson (NYSE:JNJ) Shares Sold by Callahan Advisors LLC

Callahan Advisors LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,860 shares of the company’s stock after selling 621 shares during the quarter. Johnson & Johnson accounts for approximately 2.1% of Callahan Advisors LLC’s holdings, making the stock its 12th biggest holding. Callahan Advisors LLC’s holdings in Johnson & Johnson were worth $18,317,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC lifted its holdings in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares in the last quarter. Morgan Stanley raised its stake in shares of Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares in the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $4,609,399,000. Charles Schwab Investment Management Inc. raised its stake in shares of Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of Johnson & Johnson by 61.0% in the 2nd quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock valued at $1,868,351,000 after purchasing an additional 4,278,512 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on JNJ shares. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Raymond James upped their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, March 13th. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $177.31.

Johnson & Johnson Price Performance

NYSE JNJ opened at $148.78 on Friday. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The stock has a market cap of $358.53 billion, a price-to-earnings ratio of 10.77, a price-to-earnings-growth ratio of 2.55 and a beta of 0.53. The company has a 50-day moving average price of $157.42 and a two-hundred day moving average price of $156.08.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The business’s revenue for the quarter was down 9.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.35 EPS. Analysts forecast that Johnson & Johnson will post 10.65 EPS for the current year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.